Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study

被引：9

作者：

Zamani, Mohammad ^{[1
]}

Poustchi, Hossein ^{[2
]}

Mohammadi, Zahra ^{[2
]}

Dalvand, Sahar ^{[2
]}

Sharafkhah, Maryam ^{[2
]}

Motevalian, Seyed Abbas ^{[3
,4
]}

Eslami, Saeid ^{[5
]}

Emami, Amir ^{[6
]}

Somi, Mohammad Hossein ^{[7
]}

Yazdani-Charati, Jamshid ^{[8
]}

Saki, Nader ^{[9
]}

Karami, Manoochehr ^{[10
,11
]}

Najafi, Farid ^{[12
]}

Mohebbi, Iraj ^{[13
]}

Veisi, Nasrollah ^{[14
]}

Hormati, Ahmad ^{[15
,16
]}

Pourfarzi, Farhad ^{[17
]}

Ghadimi, Reza ^{[18
]}

Ansari-Moghaddam, Alireza ^{[19
]}

Sharifi, Hamid ^{[20
,21
]}

Roshandel, Gholamreza ^{[22
]}

Mansour-Ghanaei, Fariborz ^{[23
]}

Joukar, Farahnaz ^{[24
]}

Shayanrad, Amaneh ^{[2
]}

Eghtesad, Sareh ^{[2
]}

Niavarani, Ahmadreza ^{[25
]}

Delavari, Alireza ^{[25
]}

Kaveh, Soudeh ^{[2
]}

Feizesani, Akbar ^{[2
]}

Markarian, Melineh ^{[1
]}

Shafighian, Fatemeh ^{[25
]}

Sadjadi, Alireza ^{[25
]}

Darvishian, Maryam ^{[26
]}

Malekzadeh, Reza ^{[1
,25
]}

机构：

[1] Univ Tehran Med Sci, Shariati Hosp, Digest Dis Res Ctr, Digest Dis Res Inst, Tehran 1411713135, Iran

[2] Univ Tehran Med Sci, Shariati Hosp, Liver & Pancreatobiliary Dis Res Ctr, Digest Dis Res Inst, Tehran, Iran

[3] Iran Univ Med Sci, Res Ctr Addict & Risky Behav ReCARB, Psychosocial Hlth Res Inst, Tehran, Iran

[4] Iran Univ Med Sci, Sch Publ Hlth, Dept Epidemiol, Tehran, Iran

[5] Mashhad Univ Med Sci, Pharmaceut Res Ctr, Pharmaceut Technol Inst, Mashhad, Razavi Khorasan, Iran

[6] Shiraz Univ Med Sci, Burn & Wound Healing Res Ctr, Microbiol Dept, Shiraz, Iran

[7] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran

[8] Mazandaran Univ Med Sci, Fac Hlth, Hlth Sci Res Ctr, Addict Inst,Dept Biostat, Sari, Iran

[9] Ahvaz Jundishapur Univ Med, Hearing Res Ctr, Ahvaz, Iran

[10] Hamadan Univ Med Sci, Sch Publ Hlth, Dept Epidemiol, Hamadan, Iran

[11] Shahid Beheshti Univ Med Sci, Sch Publ Hlth & Safety, Dept Epidemiol, Tehran, Iran

[12] Kermanshah UMS, Sch Publ Hlth, Res Ctr Environm Determinants Hlth, Kermanshah, Iran

[13] Urmia Univ Med Sci, Social Determinants Hlth Ctr, Orumiyeh, Iran

[14] Kurdistan Univ Med Sci, Sanandaj, Iran

[15] Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom, Iran

[16] Iran Univ Med Sci, Sch Med, Gastrointestinal & Liver Dis Res Ctr, Dept Internal Med, Tehran, Iran

[17] Ardabil Univ Med Sci, Digest Dis Res Ctr, Ardebil, Iran

[18] Babol Univ Med Sci, Hlth Res Inst, Social Determinants Hlth Res Ctr, Babol, Iran

[19] Zahedan Univ Med Sci, Hlth Promot Res Ctr, Zahedan, Iran

[20] Kerman Univ Med Sci, HIV STI Surveillance Res Ctr, Inst Futures Studies Hlth, Kerman, Iran

[21] Kerman Univ Med Sci, Who Collaborating Ctr HIV Surveillance, Inst Futures Studies Hlth, Kerman, Iran

[22] Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, Golestan, Iran

[23] Guilan Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Div Gastroenterol & Hepatol, Rasht, Iran

[24] Guilan Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Rasht, Iran

[25] Univ Tehran Med Sci, Shariati Hosp, Digest Oncol Res Ctr, Digest Dis Res Inst, Tehran, Iran

[26] BC Canc Res Ctr, Canc Control Res, Vancouver, BC, Canada

来源：

BMC PUBLIC HEALTH | 2022年 / 22卷 / 01期

关键词：

COVID-19; SARS-CoV-2; Seroprevalence; General population; Infection; POLICY;

D O I：

10.1186/s12889-022-13464-7

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Background The first large serosurvey in Iran found a SARS-CoV-2 antibody seroprevalence of 17.1% among the general population in the first wave of the epidemic by April, 2020. The purpose of the current study was to assess the seroprevalence of COVID-19 infection among Iranian general population after the third wave of the disease. Methods This population-based cross-sectional study was conducted on 7411 individuals aged >= 10 years old in 16 cities across 15 provinces in Iran between January and March, 2021. We randomly sampled individuals registered in the Iranian electronic health record system based on their national identification numbers and invited them by telephone to a healthcare center for data collection. Presence of SARS-CoV-2-specific IgG and IgM antibodies was assessed using the SARS-CoV-2 ELISA kits. The participants were also asked about their recent COVID-19-related symptoms, including cough, fever, chills, sore throat, headache, dyspnea, diarrhea, anosmia, conjunctivitis, weakness, myalgia, arthralgia, altered level of consciousness, and chest pain. The seroprevalence was estimated after adjustment for population weighting and test performance. Results The overall population-weighted seroprevalence adjusted for test performance was 34.2% (95% CI 31.0-37.3), with an estimated 7,667,874 (95% CI 6,950,412-8,362,915) infected individuals from the 16 cities. The seroprevalence varied between the cities, from the highest estimate in Tabriz (39.2% [95% CI 33.0-45.5]) to the lowest estimate in Kerman (16.0% [95% CI 10.7-21.4]). In the 16 cities studied, 50.9% of the seropositive individuals did not report a history of symptoms suggestive of COVID-19, implying an estimation of 3,902,948 (95% CI 3,537,760-4,256,724) asymptomatic infected individuals. Conclusions Nearly one in three individuals were exposed to SARS-CoV-2 in the studied cities by March 2021. The seroprevalence increased about two-fold between April, 2020, and March, 2021.

引用

页数：10

共 50 条

[21] SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study [J].

Sass, Marie Reeberg ;

Juul, Tobias Sogaard ;

Skov, Robert ;

Iversen, Kasper ;

Harritshoj, Lene Holm ;

Sorensen, Erik ;

Ostrowski, Sisse Rye ;

Andersen, Ove ;

Ekstrom, Claus Thorn ;

Ullum, Henrik ;

Nielsen, Jimmi ;

Hageman, Ida ;

Fink-Jensen, Anders .

PLOS ONE, 2022, 17 (03)

[22] High Seroprevalence of SARS-CoV-2 in Mwanza, Northwestern Tanzania: A Population-Based Survey [J].

Nyawale, Helmut A. ;

Moremi, Nyambura ;

Mohamed, Mohamed ;

Njwalila, Johnson ;

Silago, Vitus ;

Krone, Manuel ;

Konje, Eveline T. ;

Mirambo, Mariam M. ;

Mshana, Stephen E. .

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (18)

[23] Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study [J].

Ebinger, Joseph E. ;

Botwin, Gregory J. ;

Albert, Christine M. ;

Alotaibi, Mona ;

Arditi, Moshe ;

Berg, Anders H. ;

Binek, Aleksandra ;

Botting, Patrick ;

Fert-Bober, Justyna ;

Figueiredo, Jane C. ;

Grein, Jonathan D. ;

Hasan, Wohaib ;

Henglin, Mir ;

Hussain, Shehnaz K. ;

Jain, Mohit ;

Joung, Sandy ;

Karin, Michael ;

Kim, Elizabeth H. ;

Li, Dalin ;

Liu, Yunxian ;

Luong, Eric ;

McGovern, Dermot P. B. ;

Merchant, Akil ;

Merin, Noah ;

Miles, Peggy B. ;

Minissian, Margo ;

Nguyen, Trevor Trung ;

Raedschelders, Koen ;

Rashid, Mohamad A. ;

Riera, Celine E. ;

Riggs, Richard, V ;

Sharma, Sonia ;

Sternbach, Sarah ;

Sun, Nancy ;

Tourtellotte, Warren G. ;

Van Eyk, Jennifer E. ;

Sobhani, Kimia ;

Braun, Jonathan G. ;

Cheng, Susan .

BMJ OPEN, 2021, 11 (02)

[24] SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey [J].

Hoballah, Abbas ;

El Haidari, Rana ;

Siblany, Ghina ;

Sater, Fadi Abdel ;

Mansour, Samir ;

Hassan, Hamad ;

Abou-Abbas, Linda .

BMC INFECTIOUS DISEASES, 2022, 22 (01)

[25] Executive deficits after SARS-CoV-2 infection: A cross-sectional population study [J].

Buer, S. ;

Hagen, B. I. ;

Soraas, A. ;

White, R. A. ;

Bo, R. ;

Ellingjord-Dale, M. ;

Istre, M. S. ;

Brunvoll, S. H. ;

Lerdal, A. ;

Landro, N. I. ;

Nygaard, A. B. ;

Stubberud, J. .

BRAIN BEHAVIOR & IMMUNITY-HEALTH, 2024, 41

[26] Changing Patterns of SARS-CoV-2 Seroprevalence: A Snapshot among the General Population in Kuwait [J].

Alfouzan, Wadha ;

Altawalah, Haya ;

AlSarraf, Ahmad ;

Alali, Walid ;

Al-Fadalah, Talal ;

Al-Ghimlas, Fahad ;

Alajmi, Saud ;

Alajmi, Mubarak ;

AlRoomi, Ebtehal ;

Jeragh, Ahlam ;

Dhar, Rita .

VACCINES, 2023, 11 (02)

[27] SARS-CoV-2 antibody seroprevalence rates among Egyptian blood donors around the third wave: Cross-sectional study [J].

Eldesoukey, Nermeen ;

Gaafar, Taghrid ;

Enein, Azza Aboul ;

Eyada, Iman ;

Khirat, Sahar ;

ElShahawy, Asmaa ;

Diaa, Nehal ;

Youssry, Ilham .

HEALTH SCIENCE REPORTS, 2022, 5 (03)

[28] Seroprevalence of SARS-CoV-2 antibodies among homeless people living rough, in shelters and squats: A large population-based study in France [J].

Loubiere, Sandrine ;

Monfardini, Elisabetta ;

Allaria, Camille ;

Mosnier, Marine ;

Allibert, Agathe ;

Ninove, Laetitia ;

Bosetti, Thomas ;

Farnarier, Cyril ;

Hamouda, Ilyes ;

Auquier, Pascal ;

Mosnier, Emilie ;

Tinland, Aurelie .

PLOS ONE, 2021, 16 (09)

[29] Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: A cross-sectional study [J].

Szepfalusi, Zsolt ;

Schmidthaler, Klara ;

Sieber, Justyna ;

Kopanja, Sonja ;

Goetzinger, Florian ;

Schoof, Anja ;

Hoz, Jakub ;

Willinger, Birgit ;

Makristathis, Athanasios ;

Weseslindtner, Lukas ;

Stiasny, Karin ;

Bohle, Barbara ;

Krotka, Pavla ;

Graf, Alexandra ;

Frischer, Thomas .

PEDIATRIC ALLERGY AND IMMUNOLOGY, 2021, :762-770

[30] SARS-CoV-2 Seroprevalence in a Berlin Kindergarten Environment: A Cross-Sectional Study, September 2021 [J].

Bernhard, Julian ;

Theuring, Stefanie ;

van Loon, Welmoed ;

Mall, Marcus ;

Seybold, Joachim ;

Kurth, Tobias ;

Rubio-Acero, Raquel ;

Wieser, Andreas ;

Mockenhaupt, Frank .

CHILDREN-BASEL, 2024, 11 (04)

← 1 2 3 4 5 →